濟川藥業(600566.SH):擬參與認購博遠厚誠二期的出資份額3000萬元
格隆匯7月20日丨濟川藥業(600566.SH)公佈,公司為了更好地抓住醫藥行業的發展機遇,提升資產運作水平,提高資金收益,由公司全資子公司濟川有限於2021年7月20日簽訂了《蘇州博遠厚誠二期股權投資合夥企業(有限合夥)之有限合夥協議》,作為有限合夥人以自有資金參與認購博遠厚誠二期的出資份額人民幣3000萬元。
博遠厚誠二期主要通過對在中國境內設立的或其主要運營在中國境內的,有增長潛力、優質的醫療健康產業上下游及相關企業或其他經濟實體(包括但不限於運營醫藥、生物科技、醫療服務、醫療器械、設備、診斷,動物保健,及其他醫療健康相關領域的企業)的股份、股權、權益份額進行股權投資以及符合中國法律規定的以股權投資為目的的可轉債投資活動。
公司此次參與設立基金符合公司發展戰略,博遠厚誠二期主要針對在中國區域內設立的或主要運營在中國境內的醫藥、生物科技、醫療服務、醫療器械、設備、診斷,醫療IT,動物保健,及其他醫療健康相關領域的企業進行股權投資或以股權投資為目的的可轉債投資,有利於公司藉助專業投資機構的投資能力和風險控制能力,向具有良好成長性和發展前景的醫療健康領域企業進行投資,獲得投資收益。同時,公司認為博遠厚誠二期的管理團隊在醫療健康行業擁有豐富的投資經驗和廣泛的業內資源,有助於公司與相關領域的企業建立密切合作關係,發掘業務機會,對公司持續經營能力將產生積極影響,符合全體股東的利益和公司發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.